Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Review Article

From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents

Abstract

The confluence of two distinct but related activities in the past 10 years has dramatically accelerated efforts towards the discovery and development of novel drugs to treat cancer. The first is a rapidly emerging understanding that a number of distinct tyrosine kinases play roles in diverse but fundamentally important aspects of tumor progression (growth, survival, metastasis and angiogenesis). The second is the discovery that small molecule compounds have the capacity to potently and selectively inhibit the biochemical function of tyrosine kinases by competing for ATP binding at the enzyme catalytic site. These observations have been conjoined in major efforts to bring forward into clinical development novel cancer drugs with the potential to provide both clinical efficacy and improved tolerability. The focus of this review is on the development of small molecule tyrosine kinase inhibitors, and does not extend to other approaches that could be applied to disrupt the same pathways in clinical tumors (receptor and/or ligand-competitive antibodies, intrabodies, antisense ribonucleotides, ribozymes, phosphatase inhibitors or SH2/SH3-directed agents). Selected tyrosine kinase inhibitors, known or believed to be in development in cancer treatment trials, are summarized as are some of the key issues that must be addressed if these compounds are to be developed into clinically useful cancer chemotherapeutic agents.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

Abbreviations

ATP:

adenosine triphosphate

EGF/EGFR:

epidermal growth factor/EGF receptor

PDGF/PDGFR:

platelet-derived growth factor/PDGF receptor

CML:

chronic myelogenous leukemia

References

  • Allen LF, Cerna C, Gomez L, Yochmowitz M, Medina ML and Weitman S. . 2000 Proc. NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy 384.

  • Ashman LK. . 1999 Intl. J. Biochem. Cell Biol. 31: 1037–1051.

  • Barbacci EG, Cunningham A, Iwata K, Moyer JD and Miller PE. . 1997 Proc. Am. Assoc. Cancer Res. 38: 3143.

  • Bartlett RR and Schleyerbach R. . 1985 Intl. J. Immunopharmacol. 7: 7–18.

  • Baselga J, Herbst R, LoRusso P, Rischin D, Ranson M, Plummer R, Raymond E, Maddox A-M, Kaye SB, Kieback DG, Harris A and Ochs J. . 2000 Proc. Am. Soc. Clin. Oncol. 19: 686.

  • Bold G, Altmann KH, Frei J, Lang M, Manley PW, Traxler P, Wietfeld B, Bruggen J, Buchdunger E, Cozens R, Ferrari S, Furet P, Hofmann F, Martiny-Baron G, Mestan J, Rosel J, Sills M, Stover D, Acemoglu F, Boss E, Emmenegger R, Lasser L, Masso E, Roth R, Schlachter C and Vetterli W. . 2000 J. Med. Chem. 43: 2310–2323.

  • Bonomi P, Perez-Soler R, Chachoua A, Huberman M, Karp D, Rigas J, Hammond L, Rowinsky E, Preston G, Ferrante KJ and Allen LF. . 2000 Proc. NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy 386.

  • Bridges AJ. . 1999 Curr. Med. Chem. 6: 825–843.

  • Cherrington JM, Strawn LM and Shawver LK. . 2000 Adv. Cancer Res. 79: 1–38.

  • Ciardello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR and Tortora G. . 2000 Clin. Cancer Res. 6: 2053–2063.

  • Cohen RB, Falcey JW, Paulter VJ, Fetzer KM and Waksal HW. . 2000a Proc. Am. Soc. Clin. Oncol. 19: 1862.

  • Cohen S, Smolen J, Emery E, Cannon G, Weaver A and Schiff M. . 2000b Arthr. Rheum. 43: (Suppl. 9), 1221.

  • Connell RD. . 2000 Exp. Opin. Ther. Patents 10: 767–786.

  • Cropp G, Rosen L, Mulay M, Langecker P and Hannah A. . 1999 Proc. Am. Soc. Clin. Oncol. 18: 619.

  • Dowsett M, Cooke T, Ellis I, Gullick WJ, Gusterson B, Mallon E and Walker R. . 2000 Eur. J. Cancer 36: 170–176.

  • Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Muller M, Wood J, Martiny-Baron G, Unger C and Marme D. . 2000 Cancer Res. 60: 4819–4824.

  • Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J and Lydon NB. . 1996 Nat. Med. 2: 561–566.

  • Druker BJ and Lydon NB. . 2000 J. Clin. Invest. 105: 3–7.

  • Eckhardt SG, Rizzo J, Sweeney KR, Cropp G, Baker SD, Kraynak MA, Kuhn JG, Villalona-Calero M, Hammond L, Weiss G, Thurman A, Smith L, Drengler R, Eckhardt JR, Moczygemba J, Hannah AL, von Hoff DD and Rowinsky EK. . 1999 J. Clin. Oncol. 17: 1095–1104.

  • Eisenhauer EA. . 1998 Annals. Oncol. 9: 1047–1052.

  • Ferry D, Hammond L, Ranson M, Kris MG, Miller V, Murray P, Tullo A, Feyereislova A, Averbuch S and Rowinsky E. . 2000 Proc. Am. Soc. Clin. Oncol. 19: 5E.

  • Fong TAT, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP and McMahon G. . 1999 Cancer Res. 59: 99–106.

  • Fry DW. . 2000 Anti-Cancer Drug Design 15: 3–16.

  • Fry DW, Bridges AJ, Denny WA, Doherty A, Greis K, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo J, Mcnamara DJ, Nelson JM, Sherwood V, Smaill JB, Trumpp-Kallmeyer S and Dobrusin E. . 1998 Proc. Natl. Acad. Sci. USA 95: 12022–12027.

  • Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM and Leopold WR. . 1994 Science 265: 1093–1095.

  • Garber K. . 2000 J. Natl. Cancer Inst. 92: 967–969.

  • Ghosh S, Narla RK, Zheng Y, Liu X-P, Jun X, Mao C, Sudbeck EA and Uckun FM. . 1999 Anti-Cancer Drug Design 14: 403–410.

  • Gibbs JB. . 2000 J. Clin. Invest. 105: 9–13.

  • Goss G, Hirte H, Batist G, Stewart D, Miller W, Lorimer I, Abugaber A, Matthews S and Seymour L. . 2000 Proc. Am. Soc. Clin. Oncol. 19: 880.

  • Hamby JM and Showalter HDH. . 1999 Pharmacol. Ther. 82: 169–193.

  • Hamilton LC, Vojnovic I and Warner TD. . 1999 Br. J. Pharmacol. 127: 1589–1596.

  • Hammond LA, Denis LJ, Salman UA, Chintapalli K, Hidalgo M, Jeraback P, Patnaik A, Allen LF, Ferrante KJ, Carter WO, Kuhn, Drengler JR, Silberman S and Rowinsky EK. . 2000 Proc. NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy 385.

  • Hanahan D and Weinberg RA. . 2000 Cell 100: 57–70.

  • Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA and Zigler AJ. . 2000 Blood 96: 925–932.

  • Hudes G. . 1999 J. Clin. Oncol. 17: 1093–1094.

  • Hunter T. . 2000 Cell 100: 113–127.

  • Iwata K, Miller PE, Barbacci EG, Arnold LD, Doty J, DiOrio CI, Pustilnik LR, Reynolds M, Thelemann A, Sloan D and Moyer JD. . 1997 Proc. Am. Assoc. Cancer Res. 38: 4248.

  • Karp DD, Silberman SL, Csudae R, Wirth F, Gaynes L, Posner M, Bubley G, Koon H, Bergman M, Huang M and Schnipper LE. . 1999 Proc. Am. Soc. Clin. Oncol. 18: 1499.

  • Kelliher MA, McLaughlin J, Witte ON and Rosenberg N. . 1990 Proc. Natl. Acad. Sci. USA 87: 6649–6653.

  • Kelly HC, Ferry D, Hammond L, Kris M, Ranson M and Rowinsky E. . 2000 Proc. Am. Assoc. Cancer Res. 41: 3896.

  • Kuo EA, Hambleton PT, Kay DP, Evans PL, Matharu SS, Little E, McDowall N, Jones CB, Hedgecock CJ, YeaCM, Chan AW, Hairsine PW, Ager IR, Tully WR, Wwilliason RA and Westwood R. . 1996 J. Med. Chem. 39: 4608–4621.

  • Kurzrock R, Gutterman JU and Talpaz M. . 1988 N. Engl. J. Med. 319: 990–998.

  • Laird AD, Vajkoczy P. Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TAT, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G and Cherrington JL. . 2000 Cancer Res. 60: 4152–4160.

  • Lawrence DS and Niu J. . 1998 Pharmacol. Ther. 77: 81–114.

  • le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F and Gambacorti-Passerini C. . 1999 J. Natl. Cancer Inst. 91: 163–168.

  • Levitzki A and Bohmer FD. . 1998 Anti-Cancer Drug Design 13: 731–734.

  • Levitzki A. . 1999 Pharmacol. Ther. 82: 231–239.

  • Luetteke NC, Phillips HK, Qiu TH, Copeland NG, Earp HS, Jenkins NA. And Lee DC. . 1994 Genes Dev. 8: 399–413.

  • Mattar T, Kochhar K, Bartlett R, Bremer EG and Finnegan A. . 1993 FEBS Lett. 334: 161–164.

  • Medina L, Gomez L, Cerna C, Kraker A, Yochmowitz M and S Weitman S. . 2000 Proc. Am. Assoc. Cancer Res. 41: 3078.

  • Mendel DB, Laird BD, Smolich BD, Blake RA, Liang C, Hannah AL, Shaheen RM, Ellis LM, Weitman S, Shawver LK and Cherrington JM. . 2000 Anti-Cancer Drug Design 15: 29–41.

  • Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A and Miller P. . 1997 Cancer Res. 57: 4838–4848.

  • Nelson JM and Fry DW. . 2000 Proc. Am. Assoc. Cancer Res. 41: 1533.

  • Osherov N and Levitzki A. . 1994 Eur. J. Biochem. 225: 1047–1053.

  • Plate KH, Breier G, Weich HA, Mennel HD and Risau W. . 1994 Int. J. Cancer 59: 520–529.

  • Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP, Arnold LD, Doty JL, Iwata K and Morin MJ. . 1999 J. Pharmacol. Exp. Ther. 291: 739–748.

  • Randal J. . 2000 J. Natl. Cancer Inst. 92: 520–522.

  • Rosen L, Hannah A, Rosen P, Kabbinavar F, Mulay M, Gicanov N, DePaoli A, Cropp G and Mabry M. . 2000 Proc. Am. Soc. Clin. Oncol. 19: 708.

  • Rosen L, Mulay M, Mayers A, Kabbinavar F, Rosen P, Cropp G and Hannah A. . 1999 Proc. Am. Soc. Clin. Oncol. 18: 618.

  • Sausville EA. . 2000 Anti-Cancer Drug Design 15: 1–2.

  • Sedlacek HH. . 2000 Drugs 59: 435–476.

  • Shawver LK, Schwartz DP, Mann E, Chen H, Tsai J, Chu L, Taylorson L, Longhi M, Meredith S, Germain L, Jacobs JS, Tang C, Ullrich A, Berens ME, Hersh E, McMahon G, Hirth KP and Powell TJ. . 1997 Clin. Cancer Res. 3: 1167–1177.

  • Sherwood V, Bridges AJ, Denny WA, Rewcastle GW, Smaill JB and Fry DW. . 1999 Proc. Am. Assoc. Cancer Res. 40: 723.

  • Sirotnak FM, Zakowsky MF, Miller VA, Scher HI and Kris MG. . 2000 Proc. Am. Assoc. Cancer Res. 41: 3076.

  • Siu LL, Hidalgo M, Nemunaitis J, Rizzo J, Moczygemba J, Eckhardt SG, Tolcher A, Smith L, Hammond L, Blackburn A, Tensfeldt T, Silberman S and von Hoff DD. . 1999 Proc. Am. Soc. Clin. Oncol. 18: 1498.

  • Siu LL, Soulieres D, Senzer N, Agarwala S, Vokes E, Fisher D, Marsolais C, Ferrante KJ and Allen LF. . 2000 Proc. NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy 387.

  • Smolen JS and Emery P. . 2000 Rheumatol. 39: (Suppl. 1), 48–56.

  • Songyang Z and Cantley LC. . 1998 Methods Mol. Biol. 87: 87–98.

  • Sungaran R, Chislom OT, Markovic B, Khachigian LM, Tanaka Y and Chong BH. . 2000 Blood 95: 3094–3101.

  • Talpaz M, Sawyers CL, Kantarjain H, Resta D, Fernandes Reese S, Ford J and Druker BJ. . 2000 Proc. Am. Soc. Clin. Oncol. 19: 6.

  • Thompson WD, Li WW and Maragoudakis M. . 1999 J. Pathol. 187: 503–510.

  • Tzahar E, Waterman H, Chen XM, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ and Yarden Y. . 1996 Mol. Cell. Biol. 16: 5276–5287.

  • Vincent PW, Patmore SJ, Atkinson BE, Bridges AJ, Kirkish LS, Dudeck RC, Leopold WR, Zhou H and Elliott WL. . 1999 Proc. Am. Assoc. Cancer Res. 40: 117.

  • Wakeling AE, Barker AJ, Daview DH, Brown DS, Green LR, Cartlidge SA and Woodburn JR. . 1996 Breast Cancer Res. Treat. 38: 67–73.

  • Wang W-L, Healy ME, Sattler M, Verma S., Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE and Salgia R. . 2000 Oncogene 19: 3521–3528.

  • Ward WHJ, Cook PN, Slater AM, Daview H, Holdgate GA and Green LR. . 1994 Biochem. Pharmacol. 48: 659–666.

  • Wedge SR, Waterton JC, Tessier JJ, Checkley D, Dukes M, Kendrew J and Curry B. . 1999 Proc. Am. Assoc. Cancer Res. 40: 2741.

  • Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen, JO, Hennequin F, Thomas AP, Stokes ESE, Curry B, Richmond GHP and Wadsworth PF. . 2000a Cancer Res. 60: 970–975.

  • Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Hennequin F, Stokes ESE and Curry B. . 2000b Proc. Am. Assoc. Cancer Res. 41: 3610.

  • Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch K-H, Schneider MR, Drevs J, Martiny-Baron G, Totzke F and Marme D. . 2000 Cancer Res. 60: 2178–2189.

  • Woodburn JR, Barker AJ, Gibson KH, Ashton SE, Wakeling AE, Curry BJ, Scarlett L and Henthord LR. . 1997 Proc. Am. Assoc. Cancer Res. 38: 4251.

  • Workman P. . 2000 Curr. Opin. Oncol., Endocrin. Metab. Invest. Drugs 2: 21–25.

  • Xu X, Williams JW, Bremer EG, Finnegan A and Chong AS-F. . 1995 J. Biol. Chem. 270: 12398–12403.

Download references

Acknowledgements

I would like to acknowledge the outstanding contributions of each member of the Pfizer Global R&D division and the Pfizer Oncology team for their insights, support, commitment and good humor.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morin, M. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. Oncogene 19, 6574–6583 (2000). https://doi.org/10.1038/sj.onc.1204102

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204102

Keywords

This article is cited by

Search

Quick links